Analyst Price Targets — PTHS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 12:52 am | — | Roth Capital | $55.00 | $23.00 | TheFly | Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital |
| January 26, 2026 1:22 pm | — | Oppenheimer | $60.00 | $24.75 | TheFly | Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer |
| December 3, 2025 1:13 pm | — | Lake Street | $50.00 | $27.38 | TheFly | Pelthos Therapeutics initiated with a Buy at Lake Street |
| December 3, 2025 11:11 am | — | H.C. Wainwright | $60.00 | $25.14 | TheFly | Pelthos Therapeutics initiated with a Buy at H.C. Wainwright |
| November 25, 2025 9:29 am | — | Roth Capital | $57.00 | $27.53 | TheFly | Pelthos Therapeutics initiated with a Buy at Roth Capital |
| September 2, 2025 10:18 am | — | UBS | $50.00 | $22.46 | TheFly | Pelthos Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for PTHS
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTHS.
U.S. House Trading
No House trades found for PTHS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.